MARKET

CVM

CVM

CEL-SCI Corp
AMEX
3.480
+0.180
+5.45%
After Hours: 3.460 -0.02 -0.57% 16:20 10/04 EDT
OPEN
3.300
PREV CLOSE
3.300
HIGH
3.520
LOW
3.300
VOLUME
174.56K
TURNOVER
0
52 WEEK HIGH
12.82
52 WEEK LOW
2.490
MARKET CAP
150.92M
P/E (TTM)
-4.0807
1D
5D
1M
3M
1Y
5Y
CEL-SCI says neoadjuvant multikine shows response in head/neck cancer in trial
CEL-SCI (NYSE:CVM) <a href="https://seekingalpha.com/pr/189350...
Seekingalpha · 09/12 15:39
BRIEF-CEL-SCI Presents Phase 3 Data At ESMO 2022
BRIEF-CEL-SCI Presents Phase 3 Data At ESMO 2022
Reuters · 09/12 13:19
Cel-Sci Reports Positive Data From Phase 3 Study Of Neoadjuvant Multikine In Locally Advanced Head, Neck Cancer
Cel-Sci Reports Positive Data From Phase 3 Study Of Neoadjuvant Multikine In Locally Advanced Head, Neck Cancer
MT Newswires · 09/12 13:12
CEL-SCI to soon address FDA concerns on cancer therapy
Clinical-stage biotech CEL-SCI Corporation (NYSE:CVM) announce...
Seekingalpha · 09/07 14:05
Cel-Sci Corporation Issues Letter to Shareholders; Multikine Reduced And Eliminated Tumors Within 3 Weeks; Nearly 4-Year Median Overall Survival Benefit In The Radiation-Only Group; Data Presentations At ASCO And ESMO
Multikine® reduced and eliminated tumors within 3 weeks and before surgery Nearly 4-year median overall survival benefit in the radiation-only group Data presentations at ASCO and ESMO world-leading peer review
Benzinga · 09/07 12:52
CEL-SCI Corporation Issues Letter to Shareholders
VIENNA, Va., September 07, 2022--CEL-SCI Corporation issues letter to shareholders.
Business Wire · 09/07 12:45
CVM: ClinicalTrials Submission
By John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT
Benzinga · 08/29 09:12
Cel-Sci Corporation Shares Move Lower; Adam Feuerstein Tweets '$CVM posted results from Multikine ph3 study on clinicaltrials <dot> gov today, confirming the failure....Placebo patients lived longer. This drug is not getting approved, anywhere.'
https://twitter.com/adamfeuerstein/status/1560652668212719616
Benzinga · 08/19 15:44
More
About CVM
CEL-SCI Corporation is a clinical-stage biotechnology company. The Company is focused on activating the immune system to fight cancer and infectious diseases. The Company is engaged in research and developing the treatments for cancer and other diseases by using the immune system. Its lead investigational therapy Multikine (Leukocyte Interleukin, Injection) is in a pivotal phase III clinical trial. Its Multikine is an investigational immunotherapy under development for the potential treatment of certain head and neck cancers. The Company is using its Ligand Epitope Antigen Presentation System (LEAPS) technology to develop various new drug candidates, CEL-4000 and CEL-2000, as potential rheumatoid arthritis therapeutic treatments. Its product candidates using its LEAPS technology are LEAPS COV-19, CEL-2000, CEL-4000 and DerG-PG275(Cit). The Company is developing an immunotherapy with the potential to treat the coronavirus (COVID-19) using its LEAPS peptide technology.

Webull offers kinds of CEL-SCI Corporation stock information, including AMEX:CVM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CVM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CVM stock methods without spending real money on the virtual paper trading platform.